Bird & Bird scoops Eight Awards at the LMG Life Sciences Awards EMEA 2024

Our International Life Sciences Team were honoured to have been announced winners of eight prestigious awards, including 7 Impact Case / Deal awards, at the LMG Life Sciences Europe Awards Ceremony 2024 held in London.

Bird & Bird was one of the most successful firms of the night, taking home the following awards which recognised their exceptional work in patent litigation and high-profile corporate transactions:

  • Impact Deal of the Year: Envision Pharma acquisition of OKRA.ai 
  • Impact Case of the Year: Edwards Lifesciences v Meril Life Sciences 
  • Impact Case of the Year: Abbott Diabetes v Dexcom 
  • Impact Case of the Year: Xolair Litigations
  • Impact Case of the Year: Stelara Litigations
  • Impact Case of the Year: Gilead v Nucana 
  • Impact Case of the Year: Joined cases C-438/21, C-439/21, & C-440/21
  • Netherlands Firm of the Year.

The Impact Case and Deal awards are particularly highly regarded as they look to recognise firms and inhouse teams that have been involved in the more impactful case decisions and/or transactions within the life sciences industry from the previous calendar year.

To view the full list of awards and winners please click here.

The LMG Life Sciences Awards EMEA aim to recognise the most impactful, innovative and complex legal work carried out in the Life Sciences sector across a variety of different practice areas.

 

News & Deals

More News & Deals

Deal

Bird & Bird advises Vanagon Ventures on seed investment in Particula

May 07 2025

Read More

Deal

Bird & Bird advises BRIDOR on its global bakery transaction in Australia

May 07 2025

Read More

News

Bird & Bird and the Finnish Olympic Committee Enter Partnership

May 07 2025

Read More

News

Bird & Bird strengthens Corporate team with new partner Shahin Foroughian in Singapore

May 07 2025

Read More

News

Bird & Bird hires three new partners into international Corporate Group

May 06 2025

Read More

Deal

Bird & Bird advises Gamma on its admission to the Main Market of the London Stock Exchange

May 02 2025

Read More